INTERSECT ENT INC (XENT) Stock Price, Forecast & Analysis
USA - NASDAQ:XENT - US46071F1030 - Common Stock
XENT Key Statistics, Chart & Performance
The current stock price of XENT is 28.24 null. In the past month the price increased by 0.89%. In the past year, price increased by 59.91%.
XENT Latest News, Press Relases and Analysis
XENT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.3 | 228.42B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.65 | 151.48B | ||
| SYK | STRYKER CORP | 27.26 | 137.28B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.35B | ||
| IDXX | IDEXX LABORATORIES INC | 54.4 | 54.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.42 | 50.42B | ||
| RMD | RESMED INC | 24.7 | 35.69B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.84 | 33.19B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| DXCM | DEXCOM INC | 31.5 | 22.98B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.07 | 17.75B |
Related stock screener links
About XENT
Company Profile
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
Company Info
INTERSECT ENT INC
1555 Adams Dr
Menlo Park CALIFORNIA 94025 US
CEO: Thomas A. West
Employees: 433
Phone: 16506412100.0
INTERSECT ENT INC / XENT FAQ
Can you describe the business of INTERSECT ENT INC?
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
Can you provide the latest stock price for INTERSECT ENT INC?
The current stock price of XENT is 28.24 null.
What is the dividend status of INTERSECT ENT INC?
XENT does not pay a dividend.
What is the ChartMill technical and fundamental rating of XENT stock?
XENT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of INTERSECT ENT INC (XENT) based on its PE ratio?
INTERSECT ENT INC (XENT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.03).
What is the expected growth for XENT stock?
The Revenue of INTERSECT ENT INC (XENT) is expected to grow by 14.26% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for XENT stock?
You can find the ownership structure of INTERSECT ENT INC (XENT) on the Ownership tab.
XENT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to XENT. When comparing the yearly performance of all stocks, XENT is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
XENT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XENT. XENT has a bad profitability rating. Also its financial health evaluation is rather negative.
XENT Financial Highlights
Over the last trailing twelve months XENT reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS decreased by -120.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -161.94% | ||
| ROA | -132.19% | ||
| ROE | N/A | ||
| Debt/Equity | -1.52 |
XENT Forecast & Estimates
7 analysts have analysed XENT and the average price target is 28.82 null. This implies a price increase of 2.04% is expected in the next year compared to the current price of 28.24.
For the next year, analysts expect an EPS growth of 37% and a revenue growth 14.26% for XENT